Medicinal Leech Genome Assembly — Anticoagulant Gene Catalog
First chromosome-level genome for Hirudo medicinalis with 15 anticoagulation genes
Why this matters for hirudotherapy
Investigational / Research Priority
Фундаментальное научное исследование. Данный обзор охватывает геномные данные с опосредованными трансляционными последствиями для будущей разработки лекарственных препаратов.
Необходимость референсного генома
Despite centuries of use in medicine and decades of molecular research, Hirudo medicinalis lacked a high-quality reference genome until 2020. Previous genetic studies relied on fragmented transcriptome data or targeted gene sequencing. Kvist et al. addressed this gap with the first chromosome-level genome assembly, providing the foundation for systematic gene discovery.[R1]
Статистика сборки
176.96
Megabase pairs (Mbp)
19,929
Scaffolds
14
Chromosome-scale scaffolds
Каталог антикоагулянтных генов
The study’s primary contribution was a comprehensive catalog of genes encoding anticoagulation and antihemostatic proteins. The researchers annotated:
15 anticoagulation factors
Including multiple hirudin variants, Factor Xa inhibitors (lefaxin, antistasin), and thrombin-binding proteins. Several gene families showed evidence of lineage-specific duplication, suggesting evolutionary refinement of the anticoagulant repertoire.
17 antihemostatic proteins
Including platelet aggregation inhibitors (calin, saratin), fibrinolytic enzymes (destabilase), and matrix-degrading enzymes (hyaluronidase). These collectively disable every major step in the hemostatic cascade.
Новые открытия
Beyond confirming known genes, the genome assembly revealed several novel findings:
| Discovery | Significance |
|---|---|
| Lefaxin gene family | Novel Factor Xa inhibitors distinct from antistasin; potential drug leads for next-generation anticoagulants |
| Hirudin gene expansion | Multiple hirudin paralogs suggesting functional diversification — different variants may target different thrombin exosites |
| CRISP proteins | Cysteine-rich secretory proteins with unknown function; potential ion channel modulators based on homology |
| M12/M13 proteases | Metalloprotease families potentially involved in tissue penetration and extracellular matrix remodeling |
Значение для разработки лекарственных препаратов
The genome assembly enables a paradigm shift in leech-derived drug discovery. Rather than the historical approach of isolating one compound at a time through biochemical purification, researchers can now use the genome as a roadmap to identify, clone, and express candidate therapeutic proteins recombinantly.
Bivalirudin
Hirudin-inspired direct thrombin inhibitor. FDA-approved. Peak revenue $596M/year. Now generic.
Desirudin
Recombinant hirudin analog for DVT prophylaxis. FDA-approved. Demonstrates the path from leech compound to drug.
Lefaxin (preclinical)
Novel Factor Xa inhibitor identified through genomics. Represents the next generation of leech-derived drug candidates.
Complementary proteomics
References
- [R1]
A Chromosome-Level Genome Assembly for the Medicinal Leech and Identification of Anticoagulant Genes
Primary source. First chromosome-level genome assembly of Hirudo medicinalis.
- [R2]
Integrated Proteomics and Transcriptomics of Hirudo medicinalis Salivary Gland Secretion
Liu et al. proteomics study that complements the genomic catalog.
- [R3]
Comparative Transcriptomics of Three Hirudo Species
Babenko et al. extending the genomic perspective across Hirudo species.
Связанные ресурсы
Added to ASH library: February 27, 2026 | Site last updated: March 14, 2026